PXS5505-MF101
30 Nov 2021
PXS5505-MF101
NCT04676529
A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Pharmaxis
Cancer Type | Blood |
---|---|
Trial Type | Treatment |
Phase | Phase I, Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | All stages |
Anticipated Start Date | 2021-02-18 |
Anticipated End Date | 2022-06-22 |
Hospital | Icon Cancer Centre Adelaide |
---|---|
Clinical Trial Coordinator | Sue Yeend |
sue.yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Dr Stanley Cheung |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs